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INTRODUCTION 
 
Hutchinson-Gilford progeria syndrome (HGPS) is a rare 
genetic disease that occurs in approximately 1 out of 4 
million live births [1]. Visible symptoms of patients 
with HGPS include a pronounced forehead, short 
stature, receding mandible, conspicuous veins in the 
scalp, alopecia and diminished subcutaneous fat [1-4]. 
Internally, such patients undergo accelerated organ 
degeneration. The average life expectancy of HGPS 
patients is just 14 years, with death typically resulting 
from heart attacks or stroke [1-4]. 
 
The genetic mutation that leads to HGPS occurs in exon 
11 of the human LMNA  gene, which plays a role in 
nuclear scaffolding [5, 6]. This HGPS mutation is a de 
novo single nucleotide substitution (1824 C => T), 
which does not change the amino acid coding sequence 
[GGC (glycine) => GGT (glycine)]. However, this 
mutation partially activates a  cryptic  splice  donor  site,  
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which causes a 150-nucleotide sequence to be spliced 
out of exon 11 and leads to the production of the mutant 
protein progerin, also known as LAΔ50 [7]. Because of 
this internal deletion, progerin does not contain the 
cleavage site required for the removal of the farnesyl 
group by protease Zempste 24, so the farnesyl group 
remains attached to progerin [1, 8]. The farnesyl chain 
is hydrophobic and has a strong affinity for the inner 
nuclear membrane. As a result, progerin abnormally 
inserts into the nuclear membrane, resulting in bulging 
of the nuclear envelope. This abnormal nuclear shape, 
commonly referred to as “nuclear blebbing”, has been 
the hallmark cellular phenotype for HGPS cells [1, 8], 
yet the molecular and physical mechanisms of nuclear 
blebbing are not well understood. In addition, the 
presence of progerin results in alterations in histone 
methylation, a thickened nuclear lamina, genome 
instability, clustering of nuclear pores, and loss of 
heterochromatin [9]. As progerin continues to build up 
inside prematurely aged cells, the nuclear blebbing 
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Abstract:  The  premature  aging  disorder,  Hutchinson‐Gilford  progeria  syndrome  (HGPS), is  caused  by  mutant lamin  A,
which affects the nuclear scaffolding. The phenotypic hallmark of HGPS is nuclear blebbing. Interestingly, similar nuclear
blebbing has also been observed in aged cells from healthy individuals. Recent work has shown that treatment with
rapamycin, an inhibitor of the mTOR pathway, reduced nuclear blebbing in HGPS fibroblasts. However, the extent of
blebbing varies considerably within each cell population, which makes manual blind counting challenging and subjective.
Here, we show a novel, automated and high throughput nuclear shape analysis that quantitatively measures curvature,
area, perimeter, eccentricity and additional metrics of nuclear morphology for large populations of cells. We examined
HGPS fibroblast cells treated with rapamycin and RAD001 (an analog to rapamycin). Our analysis shows that treatment
with RAD001 and rapamycin reduces nuclear blebbing, consistent with blind counting controls. In addition, we find that
rapamycin treatment reduces the area of the nucleus, but leaves the eccentricity unchanged. Our nuclear shape analysis
provides an unbiased, multidimensional “fingerprint” for a population of cells, which can be used to quantify treatment
efficacy and analyze cellular aging. 
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severe [9]. Cellular division is also affected in HGPS 
cells: during mitosis, when the nuclear envelope 
disassembles, the progerin forms aggregates with 
membranes, interferes with nuclear membrane 
disassembly, and mislocalizes to the cytoplasm after 
mitosis, leading to chromosome mis-segregation and 
binucleation [10, 11].  
 
Much work has also been done in an effort to develop a 
cure for HGPS. Children with HGPS are currently 
participating in the first clinical trial, testing a drug 
therapy that uses farnesyl transferase inhibitors (FTIs), 
which block the addition of the farnesyl group to 
progerin (Progeria Research Foundation 2011)[8, 12-
14]. More recently, we showed that the macrolide 
antibiotic rapamycin can reverse the nuclear blebbing 
and other phenotypes in HGPS cells through down-
regulating progerin, which suggests its potential as a 
treatment for HGPS [15-17]. In both FTI and rapamycin 
studies, the percentages of nuclear blebbing, as scored 
by blind observers, were used as the first indication of 
the effectiveness of the drugs. However, it is not 
possible to define whether a cell is blebbed 
unambiguously because many cells in both healthy and 
diseased populations contain minor abnormalities in 
nuclear shape. Hence, the fraction of cells counted as 
blebbed can vary considerably among different 
observers, making blebbing quantification an inherently 
statistical problem.  
 
A number of studies have suggested a strong connection 
between HGPS and the normal aging processes. In 
2006, Misteli’s group reported the detection of progerin 
mRNA and protein in cells obtained from healthy 
individuals, indicating that the cryptic splice site in 
exon 11 is also used in the presence of the normal 
sequence of exon 11 [18]. Similar to the results describe 
above, we detected low levels of progerin in normal 
cells, and a significant percentage of these cells had 
mitotic defects similar to those found in HGPS cells 
[10]. Our recent study further revealed a causative 
connection between dysfunctional telomeres and the 
cryptic splicing of lamin A [19]. Moreover, studies 
using tissues taken from normal human subjects 
revealed that at any age, the cryptic splicing event takes 
place in skin, and as we grow older, progerin-positive 
fibroblasts become more abundant [20, 21]. Thus, one 
may expect a broad distribution in the severity of 
blebbing in a normal cell population and an increase in 
blebbing with aging.  
 
Here, we report an automated, quantitative method that 
we used suitable to study distributions of blebbing in a 
large cell population. In this method, the nuclear 
morphology, as visualized by immunofluorescence 
staining of lamin A/C, is quantified using image 
analysis software that extracts the nuclear boundary 
from microscopy images and then calculates measures 
such as area, perimeter, and curvature for each nucleus. 
For each set of treated cells, the curvature of all of the 
nuclei can further be visualized in a single plot. Since 
curvature is a mathematically complete description of 
shape, these plots allow for the quick assessment of the 
severity of blebbing in a population of nuclei. We 
applied our method to examine HGPS fibroblasts 
treated with either mock, rapamycin, or RAD001, a 
derivative of rapamycin with better tolerance in 
patients. We found that treatment with RAD001 or 
rapamycin decreases both blebbing and nuclear area in a 
dosage dependent manner, but leaves nuclear 
eccentricity unchanged. Our study presents a novel, 
unbiased, quantitative method for analyzing HGPS and 
aging cells. This method could be useful for future drug 
screenings for HGPS or other age related diseases, 
patient diagnostics, and quantitative modeling of 
nuclear shape.  
    
RESULTS 
 
The nuclear shape of HGPS and normal fibroblast 
cells can be automatically extracted, visualized, and 
analyzed 
 
In order to test our automatic analysis of nuclear shape, 
we first cultured fibroblasts from two HGPS fibroblast 
cell lines (HGADFN155-p15 and HGADFN167-p12, 
HGPS1 and HGPS2 respectively) and from one normal 
control (HGFDFN168-p14, normal). The cells were fed 
with fresh MEM medium containing 15% FBS and 
grown at 37°C. To visualize the nuclei, we performed 
immunofluorescence staining of the nuclear membrane 
with a mouse monoclonal antibody raised against lamin 
A/C (MAB3211). This antibody has been well 
characterized in HGPS cells and has also been used in 
studies on other laminopathies. Fluorescence images of 
about 100 randomly selected nuclei per cell line were 
taken with a Zeiss fluorescence microscope at 400X 
magnification (examples are shown in Figure 1a). A 
custom-written MATLAB program (details as described 
in Material and Methods) was used to extract nuclear 
shapes and properties of the shape, such as boundary 
curvature. In Figures 1a and b, the nuclear boundaries, 
which are colored by curvature, are shown overlaid on 
the microscopy images. Convex curvatures were kept 
positive, while concave curvatures were made negative. 
As shown by the color bar in Figure 1c, blue represents 
regions of large positive curvature, and red represents 
regions of large negative curvature. A blebbed cell, such 
as the cell shown in the top of Figure 1b, will have 
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whereas  a non-blebbed cell,  such as the cell shown  in  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the bottom of Figure 1b, will have boundary regions 
that are mostly blue and green with almost no red. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The boundary curvature of HGPS and normal nuclei. (a) The curvature of nuclei is automatically
extracted from fluorescence images of anti‐laminA/C immunostaining. Here, the curvature of HGPS and normal nuclei is
shown as a colored outline, where blue represents regions of large positive curvature, and red regions of large negative
curvature (scale bar: 10 μm). Blebbed nuclei have more regions of negative curvature, and so have more red signals. (b)
High magnification examples of the extracted boundary curvature of a blebbed, HGPS nucleus, and a more oval, normal
nucleus (scale bar: 10 μm). (c) The boundary curvature of hundreds of nuclei can be represented in a single heat map. In
these heat maps, which here correspond to two HGPS cell lines (HGPS1 and HGPS2, respectively) and one control cell
line (Normal), each vertical line is the stretched, colored outline of a single nucleus. Regions of large negative curvature
are colored blue while regions of large negative curvature are colored red. (d) The nuclei are ordered from left to right
by increasing mean negative curvature (MNC), which is shown in the line plots. (e) The MNC of populations from both
HGPS cell lines is statistically different from the population from the normal control, as illustrated in this histogram. 
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the boundary curvatures of all of the measured nuclei, 
as shown in Figure 1c. In these heat maps, each vertical 
line represents the boundary curvature of one nucleus. 
To construct such a plot, imagine cutting each colored 
boundary at the location farthest from the nucleus center 
(that location is labeled 0 on the heat map), pulling the 
boundary straight, and then lining it up next to the 
colored boundaries of the other nuclei. The heat maps of 
blebbed populations, such as the HGPS cell lines, have 
many red speckles, whereas the heat maps of unblebbed 
populations, such as the control cell line, have few red 
speckles. 
 
Within each plot, the nuclei are ordered from left to 
right by increasing mean negative curvature (MNC), a 
measure of nuclear blebbing. We defined the MNC of 
each nucleus by averaging all negative curvatures, 
excluding the positive curvatures entirely, and taking 
the absolute value. As shown in Figures 1d and 1e, the 
HGPS1 and HGPS2 cell lines have larger MNCs, and 
hence are more blebbed, than the control cell line. 
HGPS1 also has a larger MNC than HGPS2, perhaps 
because HGPS1 is at a later cellular passage, and thus 
more senesced. We found that both HGPS MNC 
distributions are statistically different from the MNC 
distribution of the control (see Figure 1e for p-values).  
 
To validate the automated nuclear shape analysis, we 
also assessed nuclear morphology using the standard 
technique: manual blind counting. Nuclei with 
protrusions or invaginations were counted as blebed, 
while other nuclei were counted as normal. We found 
that 73% of HGPS1 nuclei, 63% of HGPS2 nuclei, and 
24% of normal nuclei were abnormal. These counts are 
in quantitative agreement with the MNC distributions of 
the respective cell lines (Figure 1e). In order to better 
evaluate how the results of manual counting correlate 
with quantitative shape metrics, we had experienced 
human counters label individual nuclei as either normal 
or blebbed, and analyzed the MNC of the two 
populations. The analysis shows a positive correlation 
between MNC and the percentage of nuclei that were 
labeled as blebbed (Figure S1).   
 
Since the automated analysis extracts the boundary of 
each nucleus, we can assess nuclear morphology using 
various shape metrics besides boundary curvature. For 
each nucleus, we also calculated area, perimeter, 
number of invaginations, eccentricity and other metrics. 
In analogy to how microarray data is analyzed to find 
relationships between genes, we used correlation as a 
measure of interrelationship between the 15 different 
measures of nuclear shape determined in this study. We 
hierarchically clustered the 15 measures of nuclear 
shape and laminA/C fluorescence intensity (Figure S2). 
We found several families of nuclear measures that 
roughly correspond to size, extent of blebbing, 
eccentricity, laminA/C fluorescence intensity, and the 
standard deviation of fluorescence intensity. The 
clustering reassures us that the intensity, which is 
affected by immunostaining and imaging details, does 
not notably affect the measured MNC. The clustering 
also indicates that the standard deviation in MNC and 
the tortuosity are measures related to MNC.   Also 
related to mean MNC is the solidity, which is the ratio 
of the measured area and the area of 'convex hull,' or the 
minimal convex shape that bounds the measured shape 
of the nucleus. 
 
As a control experiment, we tested whether the cell 
density would influence the MNC. We seeded cells 
from the same HGPS cell line at densities of 3000, 
9000, and 27000 cells per well in 4-well chamber slides 
(Figure S3). The three densities did not appear to have 
different MNC distributions, nor were the measured 
MNC distributions statistically distinct.   
 
RAD001 and rapamycin similarly reduce blebbing in 
HGPS fibroblast cells 
 
Recent work has revealed that rapamycin, an mTOR 
(mammalian target of rapamycin) inhibitor, 
significantly reduces the phenotypic hallmarks of 
progeria in HGPS cells by down-regulating progerin 
[15]. Everolimus (RAD001), which is the 40-O-(2-
hydroxyethyl) derivative of rapamycin, works similarly 
to sirolimus as an mTOR inhibitor but is better tolerated 
by patients. In order to compare the efficacy of 
RAD001 to rapamycin, we treated HGPS fibroblasts 
with rapamycin, RAD001, or mock, and then analyzed 
the nuclear morphology of each treatment group. 
 
Cultured fibroblasts from an HGPS patient 
(HGADFN155-p15) and a normal individual 
(HGFDFN168-p15) were used in this experiment. The 
cells were fed every other day with fresh MEM medium 
containing 0.68 µM rapamycin, 0.1 µM RAD001, 0.5 
µM RAD001, or the same volume of vehicle (DMSO, 
0.025% v/v) for a duration of seven weeks. To examine 
the effects on nuclear morphology, we labeled cells 
with an antibody for lamin A/C and an antibody specific 
for progerin (Figure 2a). To judge the impact of 
rapamycin and RAD001, we first scored the percentage 
of nuclei with abnormal morphology in the usual way 
by manual blind counting. At least 200 randomly 
selected cells were scored by fluorescence microscopy 
for each cell line under each condition. In comparison 
with the passage-matched, mock-treated HGPS cells, 
the rapamycin or RAD001 treated HGPS cells exhibited 
   
www.impactaging.com                     122                                     AGING, February 2012, Vol.4 No.2a clear reduction in nuclear blebbing (Figure 2b). Since 
increased genome instability was reported in HGPS 
cells [15, 22, 23], we also examined whether RAD001 
treatment can improve this phenotype. Using 
immunofluorescence staining, we observed a reduction 
in 53BP1 foci in rapamycin or RAD001 treated cells, 
indicating that inhibition of mTOR prevents DNA 
damage induced in prematurely senescent cells by 
progerin (Figure S4). Quantification of progerin protein 
by western blotting analysis also revealed an over 50% 
reduction in progerin levels in rapamycin and RAD001 
treated HGPS cells (Figure 2c). We also detected a 
weaker progerin-staining signal in almost all of the 
rapamycin or RAD001 treated HGPS cells, and their 
nuclear  morphology  appeared  substantially  improved  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
compared to untreated cells (Figure 2a).  
 
As reported in Cao et al. [15], we again noticed a 
reduction in overall cell proliferation at the beginning of 
the treatments (less than two weeks) with either 
rapamycin or RAD001 compared to the mock treated 
samples. We used a tetrazolium salt-based cell 
proliferation assay (WST1 assay) to analyze this apparent 
cell growth inhibition for the concentrations of RAD001 
used in the experiment: 0, 20, 60, 100, and 500 nM. 
Figure S5 shows that all treatments for both control and 
HGPS cell lines had a similar reduction in cell 
proliferation compared to the mock treatments (less than 
40%), suggesting that any effective dose of RAD001 may 
have similar anti-hypertrophic effects [24].   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The nuclear morphology and progerin levels of rapamycin and RAD001 treated HGPS cells. (a) The phenotype
of nuclear blebbing was improved in RAD001 and rapamycin treated HGPS fibroblast cells. Cells were stained with DAPI
(blue), laminA/C antibody (red), and progerin antibody (green) to show nuclear location and morphology. The treatment
duration is for seven weeks. Mock: vehicle (DMSO, 0.025% v/v); Rap: 0.68 µM rapamycin, Rad: 0.1 µM RAD001. (Scale
bar: 10 µm) (b) Quantification of the percentage of blebbing in all treatments. At least 200 nuclei were counted blindly.
M: vehicle (DMSO, 0.025% v/v); Rap: 0.68 µM rapamycin; RAD100: 0.1 µM RAD001 treatment; RAD500: 0.5 µM RAD001
treatment. (c) Progerin was decreased in rapamycin or RAD001 treated HGPS fibroblasts. The relative amount of progerin
was quantified using quantitative western blotting analysis and compared to the mock‐treated HGPS cells. 
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In parallel to the blind counting, we took 
immunofluorescence images of about 100 randomly 
selected nuclei per treatment group and automatically 
analyzed their nuclear morphology. Heat maps, which 
display the boundary curvature of the treated HGPS 
cells, are shown in Figure 3a. From the heat maps we 
see that the mock treated cells are much more blebbed 
than the rapamycin or RAD001 treated cells, which is 
consistent with our blinded counting. Indeed, we found 
that the MNC distributions of the rapamycin and 
RAD001 treated cells were statistically different from 
that of the control group (Figure 3b). Similarly, our 
analysis showed a reduction in the number of 
invaginations in treated HGPS cells (Figure 3d).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Interestingly, we also found that the RAD001 and 
rapamycin treated nuclei had a smaller area than the 
mock treated nuclei (Figure 3c). Moreover, we noticed 
that the eccentricity, which is a measure of how 
elongated the nuclei are, did not change as a result of 
the rapamycin or RAD001 treatments (Figure 3e). Our 
analysis suggested that rapamycin or RAD001 
treatments appear to locally improve abnormal 
morphology, without affecting the overall shape of the 
nuclei, though still altering nuclear size (see 
discussion). In summary, our data suggest that, similar 
to rapamycin, RAD001 can reverse the nuclear 
phenotypes in HGPS cells through promoting progerin 
clearance. 
Figure 3. Imaging analysis of RAD001 and rapamycin treated HGPS cells. (a) Heat maps that represent the
boundary curvature of the HGPS cells treated with the vehicle (mock), 100 nM and 500 nM RAD001 (Rad), and
rapamycin (Rap). (b) MNC of populations from the mock treated HGPS cell lines is statistically different from the
populations of RAD001 or rapamycin treated cells (p < 0.001) (c‐e) Compared to the mock treated nuclei, the
RAD001 and rapamycin treated nuclei have smaller area (c) and fewer invaginations (d), but similar eccentricity (e). 
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Based on the above analysis, we suggested RAD001 
could be used at 100 nM concentration to achieve similar 
beneficial effects in HGPS cell cultures as rapamycin at 
0.68 µM as described in Cao et al. [15]. Next, we 
explored the sensitivity of the curvature analysis 
program, since quantitative image analysis is most useful 
if it can reveal small changes that are difficult to observe. 
Thus, we lowered the dosage of RAD001 to 20 or 60 nM, 
and shortened the duration of treatment to two weeks. An 
HGPS fibroblast cell line (HGADFN167-p15) and a 
control fibroblast cell line (HGFDFN168-p15) were fed 
with fresh MEM medium containing 20 nM RAD001, 
60nM RAD001 or the same volume of vehicle (0.3% 
DMSO) every other day. Nuclear curvature outline and 
heat map analyses of MNC were carried out at the end of  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
the two-week treatment (Figure 4a). Box plot analysis 
indicated a significant reduction of MNC in the HGPS 
cell line, even in the cells receiving 20 nM RAD001 
(Figure 4b), while those minor morphological 
improvements were not visible with the traditional 
blinded counting method, suggesting that the automated 
analysis is more sensitive. Importantly, we noticed a 
dosage dependent reduction in area of the nuclei of both 
treated HGPS and treated control cells (Figure 4c): the 
area of mock treated nuclei was greater than both doses 
of RAD001 treated nuclei, but the nuclei that received the 
smaller dose of RAD001 (20 nM) had greater area than 
the nuclei that received the larger dose (60 nM). This 
result suggests the improvement in nuclear shape is a 
gradual process, the area reduction is primarily due to 
non-specific effects of the drug treatment, and increment-
tal improvement during treatment can be captured and 
quantified by this curvature outline imaging analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  4.  RAD001  induces  a  gradual  change  in  nuclear  morphology  in  a  dosage  dependant
manner. (a) Heat maps that represent the boundary curvature of HGPS cells treated with the vehicle (mock) 
or 20 or 60 nM RAD001. (b) Both doses significantly reduce the mean negative curvature as shown by the 
histogram. (c) The area of mock treated nuclei is greater than both doses of RAD001 treated nuclei, but the 
nuclei that received the smaller dose of RAD001 have greater area than the nuclei that received the larger
dose. The same trend in area change is apparent to the same extent in the treated control normal fibroblasts. 
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One of the hallmarks of HGPS is the abnormal nuclear 
shape known as blebbing. This has been the main 
morphological feature identifying an HGPS cell line 
and has been used to determine the effectiveness of 
treatments for HGPS. The traditional method of 
measuring blebbing is a manual, blind count of the 
percentage of blebbed nuclei. However, this method has 
no standard criteria and is extremely time consuming. 
Sorting the nuclei into two categories, normal and 
blebbed, also obscures the fact that blebbing is not an 
either/or phenomenon, but varies continuously. The 
subjectivity and variability of the threshold for blebbed 
nuclei makes it impossible to compare values obtained 
by different counters. The need for an unbiased, 
quantitative method of measuring the degree of 
blebbing in a cell sample is clear. 
 
In an effort towards solving this issue, we present an 
automated image analysis method using curvature as the 
primary measure of blebbing. We used a custom-written 
program to extract the boundaries of immuno-stained 
nuclei and calculate a curvature contour for each 
nucleus among other measures of shape. We found that 
several measures of the shape differentiate between 
HGPS and normal control cell lines. We focused on the 
most intuitive measure, the mean negative curvature 
(MNC), which is the average of all the concave 
curvatures on the boundary of a nucleus. MNC provides 
a continuous measure of blebbing that can be used in 
quantitative and statistical methods. We analyzed 
different seeding densities (Figure S3) and exposure 
times (data not shown) to demonstrate that MNC is also 
a consistent measure that does not vary significantly 
between experiments. The cluster analysis also shows 
that intensity does not affect the measured MNC (Figure 
S2). Thus MNC values can be compared between 
samples and experiments, unlike values obtained from 
the traditional blebbing count method. One caveat is 
that MNC is affected by pixel size and smoothing, thus 
care should be taken when comparing results from 
different laboratories. Of the other measures that 
strongly correlate with MNC, according to our 
clustering analysis (Figure S2), solidity should not be 
significantly affected by pixel size or smoothing and 
thus may be a viable alternative.  
 
To better demonstrate the usefulness of this novel 
analysis, we treated HGPS and control cell lines with 
rapamycin, an mTOR pathway inhibitor that has been 
shown to improve nuclear morphology of HGPS cells, 
and with one of its analogues, RAD001, which is better 
tolerated by treated patients. The cells were treated for 7 
weeks, stained with an anti-lamin A/C antibody, and 
analyzed using the program. Results of the treatment are 
presented through heat maps and box plots of MNC in 
Figure 3. Blinded blebbing counts were also performed 
(Figure 2), demonstrating that MNC agrees with the 
established method: RAD001 and rapamycin treated 
HGPS cells had significantly improved nuclear 
morphology to the same extent. Consistent with Cao et 
al. [15], we found that RAD001 promoted progerin 
degradation (Figure 2). In addition, we reported that 
RAD001 and rapamycin treatments decreased the DNA-
damage induced 53BP1 foci formation in HGPS cells 
(Figure S4), likely through down-regulation of progerin. 
Consistent with our observation, previous studies have 
shown that rapamycin can inhibit the DNA-damage 
independent pseudo DNA-damage response, which might 
be caused by general over-activation in senescent cells 
[25, 26].   
 
To demonstrate the sensitivity of this method, we used 
this program to distinguish between treatment doses that 
cannot be differentiated by the traditional bleb counting 
method (Figure 4). We treated HGPS and control cell 
lines with lower doses of RAD001 and used Student’s t-
test to show a statistically significant increase in MNC 
with lower doses. A blinded bleb count was unable to 
demonstrate any difference between the treatments (data 
not shown). In this treatment, we again noticed a dose-
dependent change in nuclear area (Figures 3c and 4c). 
However, the same area change was observed in the 
treated normal control cell line, suggesting that this area 
change is primarily due to the action of mTOR inhibition 
and not an improvement of nuclear morphology in HGPS 
cells. We also showed the anti-hypertrophic effects of 
RAD001 in the early stages of treatment ― within the 
first week at the indicated concentrations (Figure S5). 
This reduced cellular growth in the initial period of 
treatment and the area decrease of nuclei may be 
explained by the inhibition of the mTOR pathway. After 
the initial slowdown in growth during the first two weeks 
of treatment, rapamycin and RAD001 treated cells 
showed a greatly improved proliferation rate, better than 
their mock treated counterparts [15], which is consistent 
with the previously established role of rapamycin in 
preventing the loss of proliferative potential in cultured 
cells [27]. Notably, our multidimensional analysis of cell 
shapes provides unexpected hints into the mechanical 
aspects of mTOR inhibition: while RAD001 or 
rapamycin treatment decreases blebbing and nuclear size, 
they do not alter the eccentricity of the nuclear shape 
(Figure 3e). We expect that our high throughput, multi-
dimensional measures will provide a solid foundation for 
developing mechanical models of the nucleus.  
 
HGPS is a devastating and well-studied premature 
aging disease that currently has no effective treatment. 
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aging process. In both scenarios, the broad distribution 
of nuclear shape abnormality in a single population of 
cells hampers manual analysis. Our automated nuclear 
shape analysis software provides a high-throughput and 
easy-to-use method of quantifying nuclear morphology. 
Heat maps of curvature (Figures 1, 3, 4) allow us to 
directly visualize the broad distribution of nuclear 
blebbing in a large cell population. Comparing 
measures between samples allows us to assess treatment 
efficacy for HGPS and other age-related diseases. We 
use this method to demonstrate the potential of RAD001 
as a treatment alternative for HGPS, being similarly 
effective to rapamycin. Our nuclear shape analysis 
provides an unbiased multidimensional fingerprint for a 
population of cells, which can be used to quantify 
treatment efficacy and analyze cellular aging.  
 
MATERIALS AND METHODS 
 
Cells, Cell Culture, and Treatments.  Primary human 
dermal fibroblasts used in this study were obtained from 
the Progeria Research Foundation (PRF): two HGPS 
fibroblasts, HGADFN155 and HGADFN167, and a 
control normal fibroblast line, HGFDFN168. 
Fibroblasts were cultured in MEM medium (Invitrogen) 
supplemented with 15% FBS and 2 mM L-glutamine 
under 5% CO2 at 37°C. Normal and HGPS fibroblasts 
were replenished with fresh MEM medium containing 
0.68 µM rapamycin/DMSO, or indicated concentration 
of RAD001/DMSO, every other day for up to 50 days. 
Control cells were treated with vehicle (DMSO) in 
MEM medium. Rapamycin (Sirolimus) was purchased 
from Sigma, and RAD001 (Everolimus) was obtained 
from Selleck. 
  
Immunofluorescence Staining.  For immunofluores-
cence, cells were seeded in 4-well chamber slides. After 
fixation in 4% paraformaldehyde/PBS at room 
temperature for 15 min, cells were permeabilized with 
0.5% Triton X-100/PBS at room temperature for 5 min, 
followed by an overnight incubation in the blocking 
solution (4% BSA/TBS) at 4°C. Cells were then stained 
with primary antibodies for 3 hours at room temperature 
on the following day. The primary antibodies used in 
this study were: a rabbit polyclonal antibody against 
progerin (custom peptide antibody, Yenzym); a goat 
anti-lamin A/C antibody (N-18, Santa Cruz); and a 
mouse anti-lamin A/C antibody (MAB3211, 
Chemicon). After primary antibody incubation, primary 
antibodies were detected with Alexa Fluor-labeled 
secondary antibodies (Invitrogen). Slides were mounted 
with Vectashield mounting medium containing DAPI 
and observed with a Zeiss fluorescence microscope. 
Images were taken using a 40x objective (about 100 
nuclei per condition).  Exposure times and acquisition 
settings were established at the beginning of each set of 
experiments and kept constant for all treatments.  
  
Extraction of Nuclei Boundaries.  A custom-written 
MATLAB program was used to extract nuclei 
boundaries. In order to reduce image histogram 
variability both between and within images, we first 
used contrast-limited adaptive histogram equalization. 
An 8 x 8 grid of tiles, a clip limit of 0.02, and a 
Rayleigh distribution were employed. Next, we 
binarized the images using MATLAB’s built-in 
thresholding function, which uses Otsu’s method. Holes 
within bright regions were then filled, and regions that 
either overlapped the image boundary or were smaller 
than 800 square pixels were removed. In order to 
smooth and enlarge the regions, which correspond to 
nuclei, the images were morphologically eroded with a 
disk of radius 3 pixels and then morphologically dilated 
with a disk of radius 6 pixels. The convex hulls of these 
smoothed and enlarged regions were next calculated. 
These outer convex hulls were later used as an outer 
limit on the nuclei boundary positions. Next, the images 
were morphologically eroded with a disk of radius 2 
pixels. The convex hulls of these smoothed and slightly 
enlarged regions were used to initialize an active 
contour based boundary extraction algorithm. 
 
We next processed the original images for use by the 
active contour based boundary extraction algorithm. 
First, the brightness and contrast of the image was 
adjusted so that 1% of the pixels was saturated at the 
lowest intensity and 1% was saturated at the highest 
intensity. For each nucleus, any pixel outside of its 
outer convex hull, which was found as described above, 
was set to zero, and the brightness and contrast were 
again adjusted as before. We next calculated the 
binarization threshold using MATLAB’s built-in 
thresholding function, but did not binarize the image. 
Instead, we nearly binarized the image by setting any 
pixel whose value was less than 70% of the threshold 
value to the lowest intensity and any pixel whose value 
was greater than 130% of the threshold value to the 
highest intensity. The remaining, non-saturated pixel 
intensities were then stretched to fill the entire intensity 
range. The holes in this gray-scale, nucleus image were 
next filled. 
 
An active contour, or snake algorithm, was used to 
extract nuclei boundaries with sub-pixel resolution, as 
described in Xu and Prince [28]. The gradient vector 
flow (GVF) field of the processed, nucleus image was 
calculated. The inner convex hull of the nucleus, found 
as described above, was next interpolated and used as 
the initial position of the active contour. The contour, 
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times and interpolated until the change in area from one 
set of deformations to the next was no more than 10 
square pixels. Contours were not allowed to deform 
more than 50,025 times. The GVF, snake interpolation 
and snake deformation functions are from Xu and 
Prince [28]. (The following parameters were supplied to 
these three functions: number of GVF iterations, 80; 
dmin, 0.5; dmax, 2; tension or alpha, 0.02; rigidity or beta, 
0.05; step size or gamma, 1; external force or kappa, 
0.6.) The contour was interpolated a final time, resulting 
in an outputted polygon with sides of constant length 
(dmin). 
 
Some contours do not correspond to single nuclei, but 
rather are multiple, overlapped nuclei or are auto-
fluorescent regions of cells. The user is next given an 
opportunity to remove such unwanted contours. Each 
analyzed image is sequentially displayed and polygons 
clicked on by the user are removed from further 
analysis. 
 
Analysis of Boundary Shape.  We calculated the 
boundary curvature at each boundary point by fitting a 
circle to that boundary point and the two points 25 
boundary points away from it. The curvature was then 
calculated as the reciprocal of the radius of that circle. 
Convex curvatures were kept positive, while concave 
curvatures were made negative. For each nucleus, the 
boundary point farthest from the centroid was labeled 
boundary point 0. When visualized with color, 
curvature values were cut-off such that magnitudes 
above a cut-off value were set to that cut-off value. For 
each nucleus, the number of invaginations was 
calculated by simply counting the number of boundary 
regions, of any length, where negative curvature was 
uninterrupted by positive curvature, and eccentricity 
was defined as the eccentricity of an ellipse with the 
same second-moments as the nuclear shape. The 
eccentricity of an ellipse describes how elongated the 
ellipse is; a circle would have an eccentricity of 0, and a 
line segment has an eccentricity of 1. We have 
previously similarly analyzed the shape of migrating 
amoebae [29] 
 
WST-1 Cell Proliferation Assay.  A WST-1 cell 
proliferation assay (Roche) was used to analyze the 
effects of RAD001 on cellular growth. HGPS cell line 
HGADFN167 p12 and control cell line HGADFN168 
p14 were seeded in separate standard 24-well plates at 
10,000 cells in 500 µl fibroblast medium per well. 
Wells were treated with 0, 20, 60, 100 and 500 nM 
RAD001/DMSO in triplicate and the solvent controlled 
at 0.1% for all wells. The cells were then incubated with 
treatment for 72 hours. The medium was removed from 
each well and 500 µl of 10% WST-1 reagent in 
fibroblast medium was applied to each well following 
the incubation. Three blanks, consisting of 500 µl of 
10% WST-1 reagent in fibroblast medium, were also 
created. The absorbance (450nm) of each well was read 
after 3 more hours of incubation using a SpectraMax 
M5
e plate reader (Molecular Devices), and the average 
absorbance of the blanks was subtracted from each 
measurement. 
 
Cell numbers were calculated from the absorbance 
values using a standard curve established by repeating 
the experiment without treatment and seeding at 1000, 
2000, 4000, 8000 and 16000 cells per well in duplicate. 
The percent survival was calculated for each sample by 
the equation: percent survival = 100 * (cell #)/(average 
cell # of 0 nM treatment), then averaged by treatment. 
The error was calculated using the standard deviation of 
the percent survivals of the 3 samples for each 
treatment.  
 
Statistics. Statistical analysis of MNC and other values 
was performed using the ttest2 function in MATLAB 
v7.12.0 that performs a Student’s t-test. The 
parameters were set to a 1-tailed t-test, assuming 
unequal variances, and a p-value of 0.05 or less was 
considered significant. 
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Figure S1.  Mean negative curvature (MNC)  correlates   with  bleb  counting,   Im ages  of
847  nuclei  from  HGPS  and  normal  control  cell  lines  were  separately  displayed  to  3
members of the Cao lab. Each member selected the nuclei he or she considered to be
blebbed  using  the  standard  criteria  established  in  the  Materials  and  Methods.  The
selections  were  saved  and  analyzed  through  a  custom‐written  MATLAB  program.  The
percentage of all nuclei with an MNC above a certain threshold that were labeled blebbed
by the majority of counters (2 or more) is displayed for various MNC thresholds. 
Figure S2. Covariance matrix (right) and hierarchical clustering plot (left) of 15 measures of nuclear
shape and lamin A/C fluorescence intensity. Each box in the covariance matrix indicates the amount
of correlation between two measures. High covariance is indicated in red (see color bar).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.  The  plating  density  of  the  cells  does  not  affect  the  curvature  analysis.  (a)  HGPS
fibroblast cells (HGADFN155‐p15) were seeded at various cell densities (3000, 9000, and 27000
per well) in 4‐well chamber slides and immuno‐stained with anti‐lamin A/C (N18, Santa Cruz) and
DAPI.  Images  of  the  nuclear  staining  with  DAPI  and  brightfield  images  are  presented  to  help
visualize the various cell densities. (b) Heat maps of curvature contours of 100 randomly selected
nuclei for each density and sorted by MNC show a similar degree of blebbing at all cell densities.
(c) Box plots of MNC created using MATLAB’s boxplot function of nuclei imaged in the heat maps.  
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Figure  S4.  Genome  stability  is  improved  in  rapamycin  or  RAD001  treated  cells.  (a)
Fibroblast cells were immuno‐stained with DAPI (blue) and TP53BP1 antibody (green); scale
bar: 20 µm. (b) Percentage of TP53BP1 foci‐positive cells in Rad100, Rad500, rapamycin and
mock  treated  HGPS  cells.  Mock:  mock  treatment;  Rap:  0.68  µM  rapamycin  treatment;
Rad100: 0.1 µM RAD001 treatment; Rad500: 0.5 µM RAD001 treatment. The percentage of
cells with no TP53BP1 staining is shown in blue, the percentage of cells with one TP53BP1 is
in red, and percentage of cells with more than one TP53BP1 foci is shown in yellow.  
 
 
Figure S5. A cell proliferation assay shows that all treatments of RAD001/DMSO at indicated
dosages  for  both  normal  (blue)  and  HGPS  (red)  fibroblast  cell  lines  had  similarly  reduced
growth compared to the mock treatments. All treatments were controlled for DMSO at 0.1%
and percent survival calculated relative to the cell numbers of the mock treatments. 
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